In 2016 Bhutan graduated from Gavi support as its socioeconomic status change from lower-income to lower-middle income country, hence introducing new vaccines to its routine vaccination programme can pose a long-term financial burden to the government. However, since pneumococcal infections is a maj

In the late year of 2020, the COVID-19 vaccines in the news which claim itself for possessing 90% efficacy seems to be the light at the end of the tunnel for all population in the world. All eyes are being kept on the upcoming promising vaccines while ones with lower efficacy are seen scept

Asst. Prof Hannah Clapham during the policy conference session “Charting a path to sustainable immunization programs and preparedness/response strategies” The development, delivery, access, and perceptions around vaccination were all significantly impacted by pandemics. The pand

This is the third visit of the HITAP team to the Philippines and last activity of the two vaccine evaluations project collaboration between NCPAM and HITAP with the support of Rockefeller Foundation through NICE International. The project started in March 2013 and ended in March 2014. With extensive

The Health Intervention and Technology Assessment Program (HITAP) would like to invite you to join and learn more about vaccines in a Policy Symposium and Workshop on Vaccinology for Clinical and Public Health Practice in Faridabad (near Delhi), India, on 18-21 November 2019. Join this event to

This project is part of the international Decision Support Initiative (iDSI), an innovative global partnership between leading government institutions, universities, and think tanks in the field of healthcare priority-setting. iDSI uniquely provides intellectual insight with hands-on field expertise, and delivers peer-to-peer support to policymaker

This article is part 2 of the blog series: “Knowledge Translation: The Key to Turning Mathematical Models from a Black Box into a Powerful Tool for Policy Decision-Making” In part 1 of this blog series, we discussed the role of mathematical models in supporting evidence-based public health decis

This course was organised at the request of Prof. Rakesh Aggarwal, the Director of JIPMER and Prof. Gagandeep Kang, the Executive Director of THSTI and Professor at the Christian Medical College (CMC) in Vellore, India. The main objective of the course was to build technical capacity of stakeholders

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context? Wantanee Kulpenga, b, , , , Pattara Leelahavaronga, , Waranya Rattanavipaponga, , Vorasith Sornsrivichaib, , Henry C. Baggettc, , Aronrag Meeyaia, d, , , Warunee Punpaniche, ,

Abstract Background Due to competing health priorities and limited resources, many low-income countries, even those with a high disease burden, are not able to introduce pneumococcal conjugate vaccines. Objective To determine the cost-utility of 10- and 13-valent pneumococcal conjugate vacci